Fatty liver (MASLD) and weight loss: what your results mean
Medically Reviewed by Dr. Pedro Yelamo Vera, MD
Licensed Physician No. 484814280 · Official Medical College of Bizkaia (Spain)Last reviewed: 12 October 2026
Fatty liver weight loss explained: what MASLD means, how FIB-4 and liver scans judge scarring, how much weight change helps, and when to see a specialist.
You don't have to figure this out alone
Dr. Pedro Yelamo Vera is an independent, bilingual GP licensed in Spain. Book a 15-minute video consultation in English or Spanish for €50, with a private electronic prescription issued under Spanish law when clinically appropriate.
Many people first hear about fatty liver after a routine scan or blood test. The report may say "steatosis", "NAFLD" or "MASLD". It can feel alarming, but it is common and often found early. Fatty liver weight loss advice is real and backed by evidence. This guide explains what your results mean, how doctors check for scarring, and when to see a liver specialist. It is written for expats, residents and travellers in Spain.
- Fatty liver linked to weight, blood sugar or cholesterol is now called MASLD. The old name was NAFLD.
- It is often found on an ultrasound or by mildly raised liver tests. Normal liver tests do not rule it out.
- The key question is scarring. Doctors use the FIB-4 score, then a liver stiffness scan if needed.
- Steady weight loss, more movement and less alcohol can reduce liver fat and, with larger change, inflammation and scarring.
- Yellow skin, vomiting blood, black stools, new confusion or a swollen belly need urgent care.
NAFLD is now MASLD: the new names
In 2023, liver societies from around the world agreed new names. The aim was to be more precise and to avoid blame. The changes are:
| Old name | New name | What it means |
|---|---|---|
| Fatty liver | Steatotic liver disease (SLD) | Fat in the liver, from any cause |
| NAFLD | MASLD | Fatty liver plus at least one metabolic risk factor, with little or no alcohol |
| NASH | MASH | MASLD with inflammation and liver cell damage |
| (none) | MetALD | MASLD plus more alcohol than the low-risk range |
Metabolic risk factors include a larger waist or higher weight, raised blood sugar or diabetes, high blood pressure, and high triglycerides or low "good" cholesterol. Most people with NAFLD on an old report now meet the MASLD definition.
How fatty liver is found
Fatty liver often causes no symptoms. It is usually picked up in one of two ways:
- An ultrasound scan done for another reason that shows a "bright" or fatty liver.
- Liver blood tests, such as ALT or GGT, that are a little high.
Liver tests can be normal even when there is fat or scarring. So a normal result does not end the story if you have risk factors. Your doctor will also look for other causes. These include alcohol, viral hepatitis, some medicines, iron overload and thyroid problems.
Fat is not the main worry. Scarring is.
Fat alone rarely harms the liver. What matters for the future is fibrosis, which means scarring. Over many years, scarring can build up and lead to cirrhosis. Most people with MASLD never reach that stage. But finding the few at higher risk is the main goal of testing.
The FIB-4 score
FIB-4 is a simple score worked out from your age, two liver enzymes (AST and ALT) and your platelet count. It needs no extra test, just a standard blood sample. A low score means advanced scarring is very unlikely. A middle or high score means you need a second test. The score is less reliable under 35 and over 65, and doctors adjust for this.
Liver stiffness scans
The next step is often transient elastography, known by the brand name FibroScan. It is a quick, painless scan, a bit like an ultrasound. It measures how stiff the liver is. A stiffer liver suggests more scarring. In Spain, this is usually done in a hospital digestive or liver unit. Other blood tests, such as the ELF test, are sometimes used instead.
European guidance from EASL, EASD and EASO in 2024 backs this step-by-step approach. FIB-4 comes first. Then a stiffness scan for anyone not clearly low risk. A biopsy is now rarely needed.
How much does weight loss help?
Weight loss is the best-studied treatment for MASLD. The benefit grows with the amount of change. European and US liver guidance describes a broad pattern from studies:
- A small, lasting loss of around 5% of body weight tends to reduce liver fat.
- A loss of around 7 to 10% tends to reduce inflammation.
- A loss of more than 10% is linked with less scarring in many people.
These are group averages, not targets or promises for you. Any loss that you keep up counts. Even without much weight change, more activity and better sleep can lower liver fat. Crash diets are not the answer, and very fast loss can bring gallstones. If you have had an eating disorder, tell your doctor before starting any weight plan.
No single diet is best. A Mediterranean-style pattern has good evidence. Cutting sugary drinks and highly processed foods helps. Regular movement you enjoy helps too, including strength work.
Alcohol and your liver
Alcohol and metabolic fatty liver add to each other's harm. The safest advice is to cut down as much as you can. If you already have marked scarring or cirrhosis, the advice is to stop drinking. Ask your doctor what applies to you. Be honest about how much you drink. It changes how your results are read.
The diabetes link
MASLD and type 2 diabetes often go together. Insulin resistance drives both. People with type 2 diabetes have a higher chance of liver scarring. That is why guidance suggests checking FIB-4 in people with diabetes or obesity with other risk factors. In turn, MASLD raises the risk of diabetes and heart disease. Heart health is the leading concern for most people with MASLD.
Good control of blood sugar, blood pressure and cholesterol protects both the liver and the heart. Statins are generally safe in MASLD and are often needed. Read more in our guide on type 2 diabetes remission and weight loss.
Medicines for MASH in Europe
There are now medicines aimed at the liver itself. Both are for adults with MASH and moderate to advanced scarring, but not cirrhosis. They are used alongside diet and exercise, not instead of them.
- Resmetirom (Rezdiffra) is a tablet. The EU gave it a conditional approval in August 2025.
- Semaglutide (Kayshild) is a weekly injection. The EU gave it a conditional approval for MASH in March 2026.
Conditional means more data must still be sent to regulators. These medicines are started by liver specialists after the stage of scarring is confirmed. Their supply and public funding in Spain may differ from EU approval. Medicines used for diabetes or obesity, such as GLP-1 medicines, may also help the liver. European guidance says to use them for those conditions when they are needed. To learn how they work, see how GLP-1 weight-loss medicines work.
GLP-1 medicines are not used in pregnancy. Under-18s need care led by a specialist team.
When to see a liver specialist
Your GP can manage most people with low-risk MASLD. A referral to a digestive or liver specialist is usually advised if:
- Your FIB-4 score is not low and a stiffness scan is needed or is raised.
- A scan suggests cirrhosis or a liver lump.
- Your liver tests stay high and the cause is unclear.
- You may need one of the newer MASH medicines.
Red flags: get urgent help
Seek urgent care if you have any of these:
- Yellow skin or eyes (jaundice).
- Vomiting blood, or black, tarry stools.
- New confusion, drowsiness or slurred speech.
- A swollen belly, or new swelling of the legs.
- Severe tummy pain that spreads to the back, or vomiting that will not stop, if you take a GLP-1 medicine.
- Shakiness, sweating or confusion if you take insulin or a sulfonylurea.
- Swelling of the face or throat, or trouble breathing.
For a medical emergency, call 112 or go to the nearest local emergency department. Do not wait for a video consultation or an online reply.
How a video visit can help
Dr. Pedro Yelamo Vera is a GP licensed in Spain (Colegiado No. 484814280). He also holds a Postgraduate Certificate in Clinical Nutrition. In a Weight Optimization consultation, he can go through your scan, liver tests and FIB-4 score with you. He can help plan next tests, lifestyle steps and referrals, in English or Spanish, while you are in Spain.
Medicine is one possible part of a plan. Where clinically appropriate, following a genuine evaluation. Treatment and prescriptions are issued solely at the doctor's discretion based on evidence-based clinical guidelines. Any medicine is given as a private electronic prescription under Spanish law. A video visit cannot replace a liver scan or a physical exam when you need one.
Go through your liver results with a GP
A 30-minute video visit in English or Spanish, for patients in Spain.
Frequently asked questions
Is MASLD the same as NAFLD?
Almost always. MASLD is the 2023 name for fatty liver linked to metabolic risk factors. Most people diagnosed with NAFLD now meet the MASLD definition.
Can fatty liver be reversed?
Liver fat can fall, and inflammation and early scarring can improve. Lasting weight change, activity and less alcohol are the main tools.
My liver tests are normal. Can I still have fatty liver?
Yes. Liver tests can be normal even with fat or scarring. Your doctor uses your risk factors, scans and the FIB-4 score.
What is a FIB-4 score?
It is a score from your age, two liver enzymes and your platelet count. A low score means advanced scarring is very unlikely. A higher score needs a further test.
Do I need to stop drinking alcohol?
Cutting down helps everyone with fatty liver. If you have marked scarring or cirrhosis, the advice is to stop. Ask your doctor what applies to you.
Is there a medicine for fatty liver?
For adults with MASH and moderate to advanced scarring, the EU has given conditional approval to resmetirom and to semaglutide for MASH. A liver specialist decides on these.
When should I go to the emergency department?
Go if you have yellow skin, vomit blood, pass black stools, become confused or develop a swollen belly. Call 112 in an emergency.
Sources
- Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023 (PubMed 37364790)
- EASL-EASD-EASO Clinical Practice Guidelines on the management of MASLD. J Hepatol 2024 (PubMed 38851997)
- Rinella ME et al. AASLD Practice Guidance on NAFLD. Hepatology 2023 (PubMed 36727674)
- EMA: Rezdiffra (resmetirom) overview
- EMA: Kayshild (semaglutide) overview
- NHS: Cirrhosis symptoms and when to get help
Related guides
Medical Citations & Sources
This content is written and reviewed by a licensed physician with reference to the following official health authorities.
